Dishman Carbogen Amcis Share Price
Sector: Biotechnology & Drugs
249.45 +3.90 (1.59%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
245.10
Today’s High
251.65
52 Week Low
155.00
52 Week High
307.80
247.00 +1.15 (0.47%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
245.85
Today’s High
251.25
52 Week Low
155.05
52 Week High
307.98
Key Metrics
- Market Cap (In Cr) 3870.76
- Beta 1.04
- Div. Yield (%) 0
- P/B 0.66
- TTM P/E 1037.1
- Peg Ratio -27.07
- Sector P/E 0
- D/E 0
- Open Price 245.1
- Prev Close 245.55
Dishman Carbogen Amcis Analysis
Price Analysis
-
1 Week2.05%
-
3 Months9.63%
-
6 Month-8.23%
-
YTD-9.11%
-
1 Year42.4%
Risk Meter
- 56% Low risk
- 56% Moderate risk
- 56% Balanced Risk
- 56% High risk
- 56% Extreme risk
Dishman Carbogen Amcis News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 12 Jun 2025Buy or sell: Vaishali Parekh recommends three stocks to buy today — October 17
2 min read . 17 Oct 2024Dishman Carbogen Amcis Q3 FY24 results: loss at ₹59.63Cr, Revenue increased by 1.77% YoY
1 min read . 17 Feb 2024Dishman Carbogen Amcis Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 2711.5
- Selling/ General/ Admin Expenses Total
- 1293.57
- Depreciation/ Amortization
- 293.74
- Other Operating Expenses Total
- 444.35
- Total Operating Expense
- 2554.41
- Operating Income
- 157.09
- Net Income Before Taxes
- 19.31
- Net Income
- 3.24
- Diluted Normalized EPS
- 1.1
- Period
- 2025
- Total Assets
- 9999.15
- Total Liabilities
- 4167.63
- Total Equity
- 5831.52
- Tangible Book Valueper Share Common Eq
- 94.72
- Period
- 2025
- Cashfrom Operating Activities
- 375.23
- Cashfrom Investing Activities
- -192.21
- Cashfrom Financing Activities
- -102.09
- Net Changein Cash
- 76.98
- Period
- 2024
- Total Revenue
- 2615.77
- Selling/ General/ Admin Expenses Total
- 1569.87
- Depreciation/ Amortization
- 310.86
- Other Operating Expenses Total
- 19.13
- Total Operating Expense
- 2630.39
- Operating Income
- -14.62
- Net Income Before Taxes
- -122.26
- Net Income
- -153.45
- Diluted Normalized EPS
- -6.01
- Period
- 2024
- Total Assets
- 9581.41
- Total Liabilities
- 3953.91
- Total Equity
- 5627.5
- Tangible Book Valueper Share Common Eq
- 95.27
- Period
- 2024
- Cashfrom Operating Activities
- 383.97
- Cashfrom Investing Activities
- -229.52
- Cashfrom Financing Activities
- -22.15
- Net Changein Cash
- 132.3
- Period
- 2023
- Total Revenue
- 2412.92
- Selling/ General/ Admin Expenses Total
- 1381.58
- Depreciation/ Amortization
- 280.72
- Other Operating Expenses Total
- 18.85
- Total Operating Expense
- 2355.59
- Operating Income
- 57.33
- Net Income Before Taxes
- -54.59
- Net Income
- -29.8
- Diluted Normalized EPS
- 3.6
- Period
- 2023
- Total Assets
- 9453.5
- Total Liabilities
- 3643.83
- Total Equity
- 5809.67
- Tangible Book Valueper Share Common Eq
- 115.47
- Period
- 2023
- Cashfrom Operating Activities
- 265.95
- Cashfrom Investing Activities
- -494.08
- Cashfrom Financing Activities
- 249.67
- Net Changein Cash
- 21.54
- Period
- 2022
- Total Revenue
- 2140.69
- Selling/ General/ Admin Expenses Total
- 1254.34
- Depreciation/ Amortization
- 307.59
- Other Operating Expenses Total
- 9.69
- Total Operating Expense
- 2125.46
- Operating Income
- 15.23
- Net Income Before Taxes
- -4.25
- Net Income
- 18.01
- Diluted Normalized EPS
- 8.24
- Period
- 2022
- Total Assets
- 8637.45
- Total Liabilities
- 3088.51
- Total Equity
- 5548.94
- Tangible Book Valueper Share Common Eq
- 114.05
- Period
- 2022
- Cashfrom Operating Activities
- 354.85
- Cashfrom Investing Activities
- -618.53
- Cashfrom Financing Activities
- 130.37
- Net Changein Cash
- -133.31
- Period
- 2021
- Total Revenue
- 1912.03
- Selling/ General/ Admin Expenses Total
- 1090.79
- Depreciation/ Amortization
- 307.66
- Other Operating Expenses Total
- 6.04
- Total Operating Expense
- 1951.71
- Operating Income
- -39.68
- Net Income Before Taxes
- -65.03
- Net Income
- -165.13
- Diluted Normalized EPS
- -3.97
- Period
- 2021
- Total Assets
- 8366.1
- Total Liabilities
- 2667.28
- Total Equity
- 5698.82
- Tangible Book Valueper Share Common Eq
- 125.09
- Period
- 2021
- Cashfrom Operating Activities
- 513.43
- Cashfrom Investing Activities
- -380.79
- Cashfrom Financing Activities
- -11.04
- Net Changein Cash
- 121.6
- Period
- 2020
- Total Revenue
- 2043.6
- Selling/ General/ Admin Expenses Total
- 981.39
- Depreciation/ Amortization
- 282.62
- Other Operating Expenses Total
- 11.61
- Total Operating Expense
- 1811.2
- Operating Income
- 232.4
- Net Income Before Taxes
- 197.2
- Net Income
- 158.51
- Diluted Normalized EPS
- 15.35
- Period
- 2020
- Total Assets
- 8199.81
- Total Liabilities
- 2484.75
- Total Equity
- 5715.06
- Tangible Book Valueper Share Common Eq
- 121.19
- Period
- 2020
- Cashfrom Operating Activities
- 585.14
- Cashfrom Investing Activities
- -441.75
- Cashfrom Financing Activities
- -97.78
- Net Changein Cash
- 45.61
- Period
- 2019
- Total Revenue
- 2058.59
- Selling/ General/ Admin Expenses Total
- 959.3
- Depreciation/ Amortization
- 240.38
- Other Operating Expenses Total
- 10.71
- Total Operating Expense
- 1723.97
- Operating Income
- 334.62
- Net Income Before Taxes
- 308.79
- Net Income
- 210.33
- Diluted Normalized EPS
- 16.77
- Period
- 2019
- Total Assets
- 7328.46
- Total Liabilities
- 1949.37
- Total Equity
- 5379.09
- Tangible Book Valueper Share Common Eq
- 110.77
- Period
- 2019
- Cashfrom Operating Activities
- 282.04
- Cashfrom Investing Activities
- -169.02
- Cashfrom Financing Activities
- -102.23
- Net Changein Cash
- 10.79
- Period
- 2025-03-31
- Total Revenue
- 716.34
- Selling/ General/ Admin Expenses Total
- 324.94
- Depreciation/ Amortization
- 79.09
- Other Operating Expenses Total
- 92.07
- Total Operating Expense
- 654.49
- Operating Income
- 61.85
- Net Income Before Taxes
- 27.7
- Net Income
- 43.09
- Diluted Normalized EPS
- 3.27
- Period
- 2025-03-31
- Total Assets
- 9999.15
- Total Liabilities
- 4167.63
- Total Equity
- 5831.52
- Tangible Book Valueper Share Common Eq
- 94.72
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 375.23
- Cashfrom Investing Activities
- -192.21
- Cashfrom Financing Activities
- -102.09
- Net Changein Cash
- 76.98
- Period
- 2024-12-31
- Total Revenue
- 682.34
- Selling/ General/ Admin Expenses Total
- 332.08
- Depreciation/ Amortization
- 71.97
- Other Operating Expenses Total
- 110.77
- Total Operating Expense
- 612.14
- Operating Income
- 70.2
- Net Income Before Taxes
- 27.05
- Net Income
- 4.63
- Diluted Normalized EPS
- 0.24
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 789.04
- Selling/ General/ Admin Expenses Total
- 319.73
- Depreciation/ Amortization
- 72.09
- Other Operating Expenses Total
- 130.29
- Total Operating Expense
- 716.94
- Operating Income
- 72.1
- Net Income Before Taxes
- 42.12
- Net Income
- 33.09
- Diluted Normalized EPS
- 2.32
- Period
- 2024-09-30
- Total Assets
- 10180.45
- Total Liabilities
- 4443.69
- Total Equity
- 5736.76
- Tangible Book Valueper Share Common Eq
- 84.34
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 59.25
- Cashfrom Investing Activities
- -150.09
- Cashfrom Financing Activities
- 79.63
- Net Changein Cash
- -35.69
- Period
- 2024-06-30
- Total Revenue
- 523.78
- Selling/ General/ Admin Expenses Total
- 316.82
- Depreciation/ Amortization
- 70.59
- Other Operating Expenses Total
- 111.22
- Total Operating Expense
- 570.84
- Operating Income
- -47.06
- Net Income Before Taxes
- -77.56
- Net Income
- -77.57
- Diluted Normalized EPS
- -4.71
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 654.71
- Selling/ General/ Admin Expenses Total
- 330.3
- Depreciation/ Amortization
- 85
- Other Operating Expenses Total
- 63.71
- Total Operating Expense
- 664.24
- Operating Income
- -9.53
- Net Income Before Taxes
- -49.2
- Net Income
- -69.92
- Diluted Normalized EPS
- -4.07
- Period
- 2024-03-31
- Total Assets
- 9581.41
- Total Liabilities
- 3953.91
- Total Equity
- 5627.5
- Tangible Book Valueper Share Common Eq
- 95.27
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 383.97
- Cashfrom Investing Activities
- -229.52
- Cashfrom Financing Activities
- -22.15
- Net Changein Cash
- 132.3
- Period
- 2023-12-31
- Total Revenue
- 651.09
- Selling/ General/ Admin Expenses Total
- 309.2
- Depreciation/ Amortization
- 80.37
- Other Operating Expenses Total
- 181.2
- Total Operating Expense
- 690.35
- Operating Income
- -39.26
- Net Income Before Taxes
- -66.29
- Net Income
- -59.63
- Diluted Normalized EPS
- -3.74
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Dishman Carbogen Amcis Technical
Moving Average
SMA
- 5 Day243.34
- 10 Day256.31
- 20 Day263.93
- 50 Day233.71
- 100 Day226.36
- 300 Day224.87
Dishman Carbogen Amcis Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aarti Drugs
- 452.9
- 7.45
- 1.67
- 634.9
- 312.5
- 4133.62
- Rpg Life Sciences
- 2409
- -22.98
- -0.94
- 2971.79
- 1454.6
- 3964.78
- Dishman Carbogen Amcis
- 249.45
- 3.9
- 1.59
- 307.8
- 155
- 3870.76
- Advanced Enzyme Technologies
- 329
- 4.2
- 1.29
- 571.15
- 257.85
- 3678.62
- Orchid Pharma
- 708.95
- 5.65
- 0.8
- 1998
- 603.8
- 3599.82
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aarti Drugs
- 24.62
- 3.01
- 18.24
- 8.08
- Rpg Life Sciences
- 34.16
- 7.61
- 28.51
- 16.68
- Dishman Carbogen Amcis
- 226.4
- 0.67
- -1.15
- -2.77
- Advanced Enzyme Technologies
- 27.95
- 2.58
- 11
- 22.95
- Orchid Pharma
- 35.8
- 2.82
- 2.14
- 2.75
Dishman Carbogen Amcis Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 21-May-25
- Audited Results
- 12-Mar-25
- To consider Fund Raising
- 12-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 23-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 27-Jun-25
- 26-May-25
- POM
- 02-Feb-25
- 31-Dec-24
- POM
- 27-Sept-24
- 30-May-24
- AGM
- 27-Sept-23
- 09-Aug-23
- AGM
- 29-Sept-22
- 10-May-22
- AGM
- 19-Jul-21
- 17-May-21
- AGM



